Effect of cardiac rehabilitation and statin treatment on anti-HSP antibody titers in patients with coronary artery disease after percutaneous coronary intervention

International Heart Journal

Volumn 47, Issue 5, 2006, Pages 671-682

  Shin, Young Oh ^a   Bae, Jun Sang ^a   Lee, Jeong Beom ^a   Kim, Jung Kyu ^b   Kim, Young Joo ^c   Kim, Chul ^c   Ahn, Jae Ki ^c   Bang, In Keol ^c   Lee, Byoung Kwon ^c   Othman, Timothy ^d   Min, Young Ki ^a   Yang, Hun Mo ^a  

^a Soonchunhyang University   (South Korea)

^b Kangwon National University   (South Korea)

^c Inje University   (South Korea)

^d Huntingdon Life Sciences   (United States)

Author keywords

Anti HSP antibody; Cardiac rehabilitation; Coronary artery disease; Exercise; Percutaneous coronary intervention; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LIPID; NITRIC ACID DERIVATIVE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; BLOOD ANALYSIS; CHEMICAL ANALYSIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FEMALE; HEART REHABILITATION; HOME PHYSIOTHERAPY; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; AUTOANTIBODIES; CHAPERONIN 60; CORONARY DISEASE; EXERCISE THERAPY; FEMALE; HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED;

EID: 33751187656     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.47.671     Document Type: Article

References (42)

1. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74. (Review)
2. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Imate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-91. (Review)
3. Mandal & Jahangiri M, Xu Q. Autoimmunity to heat shock proteins in atherosclerosis. Autoimmun Rev 2004; 3: 31-7. (Review)
4. Xu Q. Role of heat shock protein in atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 1547-59. (Review)
5. Xu Q, Wick G. The role of heat shock proteins in protection and pathophysiology of the arterial wall. Mol Med Today 1996; 2: 372-9. (Review)
6. Benjamin IJ, McMillan DR. Stress (heat shock) proteins: molecular cbaperones in cardiovascular biology and disease. Circ Res 1998; 83: 117-32. (Review)
7. Feige U, van Eden W. Infection, autoimmunity and autoimmune disease. EXS 1996; 77: 359-73. (Review)
8. Mayr M, Metzler B, Kiechl S, et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumontae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 1999; 99: 1560-6.
9. Schett G, Xu Q, Amberger A, et al. Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity. J Clin Invest 1995; 96: 2569-77.
10. Pockley AG, Georgiades A, Thulin T, de Faire U, Frostegard J. Serum heat shock protein 70 levels predict the development of atherosclerosis in subjects with established hypertension. Hypertension 2003; 42: 235-8.
11. Xu Q, Kiechl S, Mayr M, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study. Circulation 1999; 100: 1169-74.
12. Hoppichler F, Koch T, Dzien A, Gschwandtner G, Lechleitner M. Prognostic value of antibody titre to heat-shock protein 65 on cardiovascular events. Cardiology 2000; 94: 220-3.
13. Zhu J, Quyyumi AA, Rott D, et al. Antibodies to human heat-shock protein 60 are associated with the presence and seventy of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation 2001; 103: 1071-5.
14. George J, Shoenfeld Y, Afek A, et al. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler Thromb Vasc Biol 1999; 19: 505-10.
15. Ghayour-Mobarhan M, Lamb DJ, Vaidya N, Livingstone C, Wang T, Ferns GA. Heat shock protein antibody titers are reduced by statin therapy in dyslipidemic subjects: a pilot study. Angiology 2005; 56: 61-8.
16. Lavie CJ, Milani RV, Littman AB. Benefits of cardiac rehabilitation and exercise training in secondary coronary prevention in the elderly. J Am Coll Cardiol 1993; 22: 678-83.
17. Milani RV, Lavie CJ. Behavioral differences and effects of cardiac rehabilitation in diabetic patients following cardiac events. Am J Med 1996; 100: 517-23.
18. Lavie CJ, Milani RV. Effects of cardiac rehabilitation, exercise training, and weight reduction on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in obese coronary patients. Am J Cardiol 1997; 79: 397-401.
19. Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol 2004; 43: 1056-61.
20. Ades PA. Cardiac rehabilitation and secondary prevention of coronary heart disease. N Engl J Med 2001; 345: 892-902. (Review)
21. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today 1995; 16: 27-33. (Review)
22. Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994; 14: 32-40.
23. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-6.
24. Muhlestein JB, Home BD, Carlquist JF, et al. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation 2000; 102: 1917-23.
25. Kiechl S, Egger G, Mayr M, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001; 103: 1064-70.
26. Burian K, Kis Z, Virok D, et al. independent and joint effects of and bodies to human heat-shock protein 60 and Chlamydia pneumoniae infection in the development of coronary atherosclerosis. Circulation 2001; 103: 1503-8.
27. Xu Q, Schett G, Perschinka H, et al. Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation 2000; 102: 14-20.
28. Chen W, Syldath U, Bellmann Y, Burkart V, Kolb H. Human 60-kDa heat-shock protein: a danger signal to the innate immune system. J Immunol 1999; 162: 3212-9.
29. Kocsis J, Veres A, Vatay A, et al. Antibodies against the human heat shock protein hsp70 in patients with severe coronary artery disease. Immunol Invest 2002; 31: 219-31.
30. Leon AS, Franklin BA, Costa F, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation 2005; 111: 369-76.
31. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004; 116: 682-92. (Review)
32. Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology 2002; 13: 561-8.
33. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994; 344: 1383-9.
34. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
35. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-65.
36. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230-5.
37. Takemoto M, Liao JK. Pleiotropic effects of 3-bydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-9. (Review)
38. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003; 108: 426-31.
39. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newhy recognized type of immunomodulator. Nat Med 2000; 6: 1399-402.
40. Lee CH, de Feyter P, Serruys PW, et al. Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS). Heart 2004; 90: 1156-61.
41. Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108: 1560-6.
42. Inami S, Okamatsu Y., Takano M, et al. Effects of statins on circulating oxidized low-density lipoprotein in patients with hypercholesterolemia. Jpn Heart J 2004; 45: 969-75.